This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.
Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia
Moca score of 11 or higher
Stable psychotropics and cognitive enhancing medications
Known hypersensitivity or allergy to fisetin
Presence of any medical condition, or abnormal routine blood test, that the investigator believes would put the subject at risk or would preclude the patient from completing all aspects of the trial
Unstable medical disorders
Ongoing treatment for active infection with antibiotics/antifungals
Single group
Fisetin
Other interventionFisetin 20mg/kg/day
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability of fisetin)
Measured using AE reports
Click on the lead sponsor to view all of their trials.
Sunnybrook Health Sciences Centre
Lead sponsor
Sunnybrook Research Institute
Collaborator
